...
首页> 外文期刊>Cost Effectiveness Resource Allocation >Cost-effectiveness analysis of newborn pulse oximetry screening to detect critical congenital heart disease in Colombia
【24h】

Cost-effectiveness analysis of newborn pulse oximetry screening to detect critical congenital heart disease in Colombia

机译:新生儿脉冲血氧筛查筛查的成本效益分析检测哥伦比亚临界先天性心脏病

获取原文
           

摘要

In many countries, economic assessments of the routine use of pulse oximetry in the detection of Critical Congenital Heart Disease (CCHD) at birth has not yet been carried out. CCHDs necessarily require medical intervention within the first months of life. This assessment is a priority in low and medium resource countries. The purpose of this study was to assess the cost-effectiveness (CE) relation of pulse oximetry in the detection of cases of CCHD in Colombia. A full economic assessment of the cost-effectiveness type was conducted from the perspective of society. A decision tree was constructed to establish a comparison between newborn physical examination plus pulse oximetry, versus physical examination alone, in the diagnosis of CCHDs. The sensitivity and specificity of pulse oximetry were estimated from a systematic review of the literature; to assess resource use, micro-costing analyses and surveys were conducted. The time horizon of the economic evaluation was the first week after birth and until the first year of life. The incremental cost-effectiveness ratio (ICER) was determined and, to control for uncertainty, deterministic and probabilistic sensitivity analysis were made, including the adoption of different scenarios of budgetary impact. All costs are expressed in US dollars from 2017, using the average exchange rate for 2017 [$2,951.15 COP for 1 dollar]. The costs of pulse oximetry screening plus physical examination were $102; $7 higher than physical examination alone. The effectiveness of pulse oximetry plus the physical examination was 0.93; that is, 0.07 more than the physical examination on its own. The ICER was $100 for pulse oximetry screening; that is, if one wishes to increase 1% the probability of a correct CCHD diagnosis, this amount would have to be invested. A willingness to pay of $26.292 USD (direct medical cost) per probability of a correct CCHD diagnosis was assumed. At current rates and from the perspective of society, newborn pulse oximetry screening at 24?h in addition to physical examination, and considering a time horizon of 1?week, is a cost-effective strategy in the early diagnosis of CCHDs in Colombia.Trial registration "retrospectively registered".
机译:在许多国家,尚未进行在出生中检测临界先天性心脏病(CCHD)中常规使用脉搏血氧性的经济评估。 CCHDS必须在生命的第一个月内需要医疗干预。该评估是低中资源国家的优先事项。本研究的目的是评估脉搏血氧算法的成本效益(CE)关系在哥伦比亚CCHD病例中的检测中。从社会的角度进行了对成本效益类型的全面经济评估。构建了一个决策树以建立新生体检加脉冲血氧血管血管血管血管血管血管血管血管血管血管的比较,在CCHDS的诊断中单独进行体检。脉搏血氧测定的敏感性和特异性估计了对文献的系统审查;为了评估资源使用,进行微成本分析和调查。经济评价的时间范围是出生后的第一周,直到生命的第一年。确定增量成本效益率(ICER),并控制不确定性,制定了确定性和概率敏感性分析,包括采用不同的预算影响方案。所有费用于2017年以美元表示,2017年的平均汇率为2017年[2,951.15澳元为1美元]。脉搏血液筛分筛查加上体检的成本为102美元;单靠7美元的身体检查。脉搏血氧血滴加上物理检查的有效性为0.93;也就是说,0.07多于自己的体检。脉冲血液筛查筛查是100美元的推出;也就是说,如果一个人希望增加1%的正确CCHD诊断的概率,则必须投资这一金额。假设每次愿意支付26.292美元(直接医疗成本)的正确CCHD诊断的概率。目前,从社会的角度来看,新生儿脉冲血液血液筛查除了体检外,并考虑到1?周的时间范围,是哥伦比亚CCHDS早期诊断的经济效益策略.Trial注册“回顾性注册”。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号